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Abstract  
A systematic review and meta-analysis of available randomised controlled trials (RCTs) was 
conducted to evaluate the effect of zinc (Zn) intake on growth in infants. Out of 5500 studies 
identified through electronic searches and reference lists, 19 RCTs were selected after applying 
the exclusion/inclusion criteria. The influence of Zn intake on growth was considered in the 
overall meta-analysis. Other variables were also taken into account as possible effect modifiers: 
doses of Zn intake, intervention duration, nutritional status and risk of bias. From each select 
growth study, final measures of Weight, Length, Mid upper arm circumference (MUAC), Head 
circumference, Weight for age z-score (WAZ), Length for age z-score (LAZ) and Weight for 
Length z-score (WLZ) were assessed. Pooled β and 95% confidence interval (CI) were 
calculated. Additionally we carried out a sensitivity analysis. Zn intake was not associated to 
Weight, Length, MUAC, Head Circumference and LAZ in the pooled analyses. However, Zn 
intake had a positive and statistically effect on WAZ (β = 0.06; 95%CI 0.02 to 0.10) and WLZ (β 
= 0.05; 95%CI 0.01 to 0.08).  The dose response relationship between Zn intake and these 
parameters indicated that a doubling of Zn intake increased WAZ and WLZ by approximately 
4%. Substantial heterogeneity was present only in Length analyses. (I² = 45 %; p = 0.03). Zn 
intake was positively associated with length values at short time (4 to 20 weeks) ( = 0.01; CI 
95% 0 to 0.02) and at medium doses of Zn (4.1 to 8 mg/day) ( = 0.003; CI 95% 0 to 0.01). 
Nevertheless, the effect magnitude was small. Our results indicate that Zn intake increases 
growth parameters of infants. Nonetheless, interpretation of these results should be carefully 
considered. 
Keywords: EURRECA, zinc intake, growth, infants
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Introduction 
Zinc (Zn) is an essential nutrient, present in all body tissues and fluids. The biologic role of Zn is 
now recognized in structure and function of proteins, including more than 300 enzymes, 
transcription factors, hormonal receptor sites, and biologic membranes. Zn has numerous central 
roles in DNA and RNA metabolism (MacDonald 2000), and it is involved in signal transduction, 
gene expression, and apoptosis. Zn enzymes are involved in nucleic acid metabolism, cellular 
proliferation, differentiation and growth (Chesters 1978). Zn is a critical micronutrient for 
normal growth, haematopoiesis, immune function and neurologic development during infancy. 
Infants have a relatively high requirement of Zn per unit body weight during a sensitive period of 
rapid growth and development (Hermoso et al. 2010).                                                                                                                           
Physiological functional consequences (e.g. growth retardation) of mild Zn deficiency are often 
apparent before the Zn concentrations in plasma and/or tissues are significantly reduced (Gibson 
et al. 1989; Ruz et al. 1991). Inadequate Zn intake is likely to be an important contributing factor 
of growth failure in children that are malnourished, because diets lows in protein tend to be low 
in Zn (Golden & Golden 1981). Growth faltering starts at 6 mo of age in less-developed 
countries with rapid progression (The World Bank 2006) and coincides with a critical time in the 
dietary supply of Zn, labelled as a ‘‘problem’’ nutrient in complementary feeding by WHO. 
(Dewey & Brown 2003)  
Human Zn deficiency was described since the early 1960s. But it was not until 1990, when the 
Zn became to be a micronutrient of major interest until the current date, due the important 
function for immune system integrity (Shankar & Prasad 1998), the know losses of  Zn in 
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diarrheal fluids (Ruz & Solomons 1990), and pilot data on the association between Zn deficiency 
and diarrhea (Hambidge 1992). Zn supplementation RCT´s focused on growth velocity in young 
children. A comprehensive meta-analysis of results of 33 studies provided convincing evidence 
of a significant increase in linear growth (Brown et al. 1998; IZNCG 2004). 
A considerable number of intervention trials have been completed in multiple countries to assess 
the effect of supplemental Zn on children’s growth. However, these studies have yielded 
inconsistent results, possibly because of differences in 1) the pre-existing Zn status of the study 
subjects, 2) the content and bioavailability of Zn in the local diets, and 3) the incidence of 
common infections that can affect growth independently of an individual’s Zn status. Moreover, 
methodology aspects of these studies, such as variations in the dose, the sample sizes, the method 
of administration or the duration of supplementation, may have influenced their results (Brown et 
al. 2002).  
Recommendations for Zn intake during infancy vary widely across Europe, ranging from 1 
mg/day up to 5 mg/day (Hermoso et al. 2010). The EURRECA project attempts to consolidate 
the basis for the definition of micronutrient requirements across Europe, taking into account 
relationships among intake, status and health outcomes, in order to harmonise these 
recommendations (Ashwell et al. 2008). This paper presents a systematic review of the data from 
all available randomized controlled trials (RCTs) meeting EURRECA’s quality standard 
(Matthys et al. 2011), which investigated Zn intake and growth parameters in infants, and 
combines these studies in meta-analyses to model of growth as a function of Zn intake.  
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Materials and Methods 
Search strategy 
This research was conducted within the framework of the European Micronutrient 
Recommendations Aligned (EURRECA) Network of Excellence that aims to identify the 
micronutrient requirements for optimal health in European populations (http://www.eurreca.org).  
This review was part of a wider review process to identify studies assessing the effect of Zn 
intake  
on different outcomes (health outcomes). The wider searches were performed for literature   
published up to and including February 2010. The databases MEDLINE, EMBASE and 
Cochrane 
were accessed using search terms ‘study designs in humans’ and ‘zinc’ and ‘intake’. Both 
indexing  
and text terms were used and languages included were restricted to those spoken in the 
EURRECA  
Network (English, Dutch, French, German, Hungarian, Italian, Norwegian, Polish, Spanish, 
Greek  
and Serbian.). The Ovid MEDLINE search strategy can be found in Table 1. Reference lists of  
retrieved articles and published literature reviews were also checked for relevant studies. The 
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procedure for the identification, selection of articles and data extraction is illustrated in Fig. 1. 
 
Selection of articles 
Titles of articles identified from the searches were entered into an EndNote library. Papers were 
considered eligible for inclusion if they were RCTs, conducted in human infants (aged 0-12 
months), and studied the effect of supplements, fortified foods or micronutrient intake from 
natural food sources, and assessed Zn concentrations in serum/plasma. Zn intake was assessed 
from breast milk, infant formula and food sources (e.g. fortified formula or cereal) and 
supplements. 
Exclusion criteria applied were: studies conducted in animals; combined interventions e.g. >1 
micronutrient or micronutrient + lifestyle intervention which did not study the effect of the 
micronutrient separately; non primary studies (e.g. letters and narrative literature reviews); 
duplicate publications; studies where the Zn intake - growth relationship was not reported or 
health outcomes other than growth assessed. 
Briefly, titles and abstracts of the 10% of the library were screened in duplicate for eligibility by 
two reviewers and any discrepancies were discussed and resolved before screening the remaining 
references. Only when both reviewers agreed that titles and abstracts met the inclusion criteria 
were the articles included. When a title and abstract could not be included with certainty, the full 
text of the article was obtained and then further evaluated. The remaining 90% was distributed 
among the reviewers in even parts. Following the initial screening process, full-text articles were 
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obtained. Further inclusion and exclusion criteria were then applied. Papers were only included 
in the meta-analysis if they were: RCTs; had an intervention duration of at least 2 weeks and 
reported baseline data for all outcome measures. Non-RCTs, uncontrolled trials or trials 
reporting insufficient or unclear data were excluded. Data was extracted from each study and 
organized in a Microsoft Access database file (Microsoft Corp, Redmond, WA, USA). 
 
Data synthesis  
When growth was measured at different time points within the same population, we used the 
measures as different estimations (Hamadani et al. 2001; Heinig et al. 2006; Sur et al 2003). One 
study reported data separately for boys and girls (Walravens et al. 1989). One study report data 
from two groups of infants (stunted and non stunted) and also these were treated as two different 
estimations within the meta-analysis (Umeta et al. 2000). Different estimations were also 
considered for the following studies: the study of Osendrap et al. 2002 that analyzed three groups 
of infants (all, infants with low serum Zn < 9.18 µmol/L, and infants with normal serum Zn > 
9.18 µmol/L) and the study of Arsenault et al. 2008 that assessed two groups (Zn intake in a 
liquid supplement and in a fortified porridge).   
If dietary intake of Zn (in addition to the intervention) was not reported in the RCTs we imputed 
a value of 1.3 mg/day, the mean dietary intake level of the RCTs that did report dietary Zn 
intake. As mean baseline growth parameters were infrequently reported in the RCTs, most of the 
RCTs assumed no differences in baseline measures (n= 16). Arsenault and Rivera et al. (2008; 
1998) performed an adjustment for initial differences. Only the study of Bates et al. (Bates et al. 
1993) failed to report anything regarding this matter. 
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Exposure and outcome and other covariates assessment: 
The influence of Zn intake on growth parameters was considered in the overall meta-analysis. 
From each select growth study, final measures were assessed: Weight, Length, MUAC, Head 
circumference, WAZ, LAZ and WLZ in all the included studies.  
Other variables were also taken into account as possible effect modifiers. We considered doses 
of Zn intake (1 to 4 mg, 4.1 to 8 mg, 8.1 to 12 mg and >12.1 mg), intervention duration (1 to 3 
weeks, 4 to 20 weeks and > 20 weeks), nutritional situation (healthy, nutritionally at risk and 
poor nutritional status) and risk of bias (low, moderate or high).  
 
Assessment of nutritional situation in included studies 
Poor nutritional status was defined as infants with low birth weight during their first year, 
undernourished or current growth retardation evidenced by a WAZ and LAZ scores below -2; 
nutritionally at risk was defined as infants who lived in low-income families with a low 
socioeconomic situation. 
 
Assessment of risk of bias in included studies 
Risk of bias was assessed in order to evaluate the quality of the studies included. The following 
indicators of internal validity specific to the RCT methodology were collected during data 
extraction: 1) method of sequence generation 2) adequate allocation, 3) blinding, 4) number of 
participants at start, dropouts and dropout reasons, 5) outcome data complete, 6) funder 
adequate, 7) other potential funding bias. Based on these indicators, two reviewers assessed the 
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overall risk of bias. Disagreements were resolved by discussion. The criteria for judging these 
indicators were adapted from the Cochrane Handbook for Systematic Reviews (Higgins JPT & 
Green S 2009).  
 
Statistical analysis 
Mean and standard deviation (SD) or standard errors (SE) of the outcome (Weight, Length, 
MUAC, Head circumference, WAZ, LAZ and WLZ) were assessed. From the mean and SD of 
each study, beta values (β) and their SE were calculated because the statistical model that we 
used to estimate the relation between Zn intake (x-variable) and growth (y- variable) is based on 
the assumption that this intake-growth linear relationship is a logarithmic function and that both 
intake and growth follow a log-normal distribution (the natural logarithm of intake and growth 
have a normal distribution). Thus, the expected value of the growth score is expressed as: 
µy = β * µx + intercept 
where µy represents the mean of the natural logarithm of the y–variable (= growth score), β 
represents the regression coefficient, and µx represents the mean of the natural logarithm of the 
x-variable (= Zn intake). 
This shape of this linear relationship on the loge–loge-scale corresponds to a monotonic concave 
function on the original scale for β < 1. This shape is assumed to be realistic for the biological 
relationship between Zn intake and growth parameters. As the true dose-response curve is 
unknown, this approximation provides a practical methodology to estimate the dose-response 
relationship. 
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The method used to systematically review differences was a formal meta–analysis (Greenland 
1998).  
Procedures of formal meta-analysis have been applied to combine the results from previously 
reported studies (Dickersin 2002). 
A random-effects model was considered to be more appropriate than a fixed-effects model. We 
used the DerSimonian and Laird’s (DerSimonian & Laird 1986) to pool the estimates of betas 
across studies. Under this model, the pooled effect was the beta in the growth parameters 
(Weight, Length, MUAC, Head circumference, WAZ, LAZ and WLZ), for an increment of 1 
unit in Zn intake. A pooled beta estimate was calculated as a weighted average of the beta 
reported in each study. 
The formula we used to estimate the weighted effect size was (Hedges 1982): 
β pooled = ∑ βi wi  ⁄ ∑ wi 
where β pooled is the pooled estimate of the beta in growth parameters; the weight (wi) of each 
study was computed as:  
wi = 1 / Vi + ح² 
where V is the variance of each study and   ح ²  is the inter-study variance. 
Besides this, we calculated a 95% CI for the pooled estimated of effect size:     
95% CI= β pooled ± (1.96 x SE pooled) 
where SE is the standard error of the pooled estimate (Greenland 1998). 
A test of heterogeneity was calculated, estimating Q statistics, which follows a chi-square 
distribution with degrees of freedom n-1, n being the number of studies included in the analysis. 
The I² Index measures the extent of the heterogeneity. A low P value for this statistic (lower than 
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0.05) indicates the presence of heterogeneity, which somewhat compromises the validity of the 
pooled estimates (Takkouche et al. 1999). Because significant heterogeneity was clearly evident 
in the pooled beta estimates for Length studies, we evaluated potential sources of heterogeneity 
by linear meta-regressions (Greenland 1998). We fitted a meta-regression using the duration of 
the intervention, the doses of Zn intake, the risk of bias and the nutritional situation as 
independent variables. The betas obtained in each study for the Length parameter according to 
Zn intake were used as the dependent variable.  
Statistical differences in multivariate adjusted mean beta values between each possible 
heterogeneity sources were determined by analysis of covariance ANCOVA. Additionally we 
carried out additional meta-analyses by subgroups considering only those groups which provided 
significant values in the meta-regression.  
Sensitivity analyses were also conducted. We excluded the studies considered outliers and 
recalculated the pool estimate of the beta in each growth parameter. 
Microsoft Excel Version (7.0), SPSS 10.0 for Windows and Review Manager 5.1, were used to 
conduct the statistical analyses. 
 
Results 
Five thousand five hundred articles were identified in the initial search strategy. After applying 
the exclusion/inclusion criteria, 344 articles from the search appeared to be potentially relevant. 
After applying the additional eligibility criteria and grouping the studies by outcome, nineteen 
RCTs (38 estimations) were selected for the growth meta-analysis (Arsenault et al. 2008; Bates 
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et al. 1993; Berger et al. 2006; Dijkhuizen et al. 2001; Fischer Walker et al. 2009; Gardner et al. 
2005; Hamadani  et al. 2001; Heinig  et al. 2006; Lind  et al. 2004; Meeks Gardner et al. 1998; 
Müller et al. 2003; Ninh et al. 1996; Olney  et al. 2006; Osendarp  et al. 2002; Rivera  et al. 
1998; Sur et al. 2003; Umeta et al. 2000; Walravens et al. 1989; Wasantwisut et al. 2006). (Fig. 
1) 
Descriptive characteristics of the studies included in the meta-analysis are presented in Table 2. 
Of the nineteen studies included, only twelve comply strictly with the age infants (0 to 12 
months) (Arsenault et al. 2008; Berger et al. 2006; Dijkhuizen et al. 2001; Fischer Walker et al. 
2009; Heinig et al. 2006; Lind et al. 2004; Olney et al. 2006; Osendarp et al. 2002; Rivera et al. 
1998; Sur et al. 2003; Umeta et al. 2000; Wasantwisut et al. 2006). The other seven studies 
included this age among their sample, but did not clarify how many are actually aged 0 to 12 
months (Bates et al. 1993; Gardner et al. 2005; Hamadani et al. 2001; Meeks Gardner et al. 1998; 
Müller et al. 2003; Ninh et al. 1996; Walravens et al. 1989). None of the ages extended beyond 
27 month, except Gardner et al. and Ninh et al. (2005; 1996), which included children up to 30 
and 36 months respectively.  
 
Four studies were conducted in Latin America and the Caribbean, two in North America, nine in 
Asia and four in Africa. The duration of the interventions ranged from 2 to 60 weeks. Some 
studies assessed growth parameters at several time points within the study (Hamadani et al. 
2001; Heinig et al. 2006; Sur et al. 2003). Doses of Zn intake ranged from 1.78 to 20 mg per day. 
The nutritional situation of infants also varied between studies: six studies were conducted in 
healthy infants (Bates et al. 1993; Heinig et al. 2006; Lind et al. 2004; Osendarp et al. 2002; 
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Umeta et al. 2000; Wasantwisut et al. 2006), six studies were conducted on infants who were 
nutritionally at risk (Arsenault et al. 2008; Berger et al. 2006; Fischer Walker et al. 2009; Müller 
et al. 2003; Rivera  et al. 1998; Walravens et al. 1989), and seven studies were conducted on 
infants with poor nutritional status (Dijkhuizen et al. 2001; Gardner et al. 2005; Hamadani  et al. 
2001; Meeks Gardner et al. 1998; Ninh et al. 1996; Olney et al. 2006; Sur et al. 2003). The risk 
of bias varied also between studies: six studies had a high risk of bias, seven had a moderate risk 
and six showed a low risk of bias. 
Differences in Growth outcomes (Weight, Length, MUAC, Head Circumference, WAZ, LAZ 
and WLZ) according to Zn intake in each particular study and in the pooled analyses are showed 
in Figures 2 to 8. Zn intake was not associated to Weight, Length, MUAC, Head Circumference 
and LAZ in the pooled analyses. However, Zn intake had a positive and statistically effect on 
WAZ (β = 0.06; 95%CI 0.02 to 0.10) and WLZ (β = 0.05; 95%CI 0.01 to 0.08).  
Since we applied a base-e logarithmic transformation on the Zn intake and growth parameters 
before calculation of the study-specific β´s, the overall β represents the difference in the 
logetransformed predicted value of WAZ and WLZ for each one-unit difference in the 
logetransformed value in Zn intake. Therefore, an overall β of 0.06 means that for every doubling 
in Zn intake, the difference in WAZ is  (20.06 = 1.04). For an overall β of 0.05, the difference in 
WLZ is 1.035. That means that a person with a double intake of Zn has aproximately 4% higuer 
WAZ and WLZ than a person with the half intake. (Fig. 9, 10) 
Excepting for Length (I² = 45 %, p= 0.03), heterogeneity was not present in any analysis. In 
order to investigate which variables may be potential effect modifiers on Length, we performed a 
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meta-regression (Table 3). The effect of Zn intake on Length changed depending on the duration 
of the intervention and the dose (p ANCOVA= 0.008 and 0.023) respectively. 
Table 4 shows the results of Length analyses after stratifying the studies according to the effect 
modifiers identified in the meta-regression. After stratifying by duration of the intervention and 
by dose, the heterogeneity disappeared. At short time (4 to 20 weeks), Zn intake was positively 
associated with length values (=0.01; CI 95% 0 to 0.02). However, no effect was found when 
supplementation lasted for more than 20 weeks ( = -0.001; CI 95% -0.003 to 0.002). At medium 
doses of Zn (4.1 to 8 mg/day), Zn intake was positively associated with length values (= 0.003; 
CI 95% 0 to 0.01). Nevertheless, the effect magnitude was small. However, no effect was found 
at low or high doses of Zn (1 to 4 or >12 mg/day) (= 0; CI 95% -0.01 to 0.004 and = 0.01; CI 
95% -0.02 to 0) respectively.  
The results of the sensitivity analyses are shown in Table 5. The study of Osendrap et al. (b) 
(2002), Walravens et al. (a) and Walravens et al. (b) (1989) were considered as outliers in the 
analysis of weight because the limits of beta were very wide (from CI 95% 0.01 to 0.23; CI 95% 
-0.04 to 0.10 and CI 95% -0.04 to 0.10) respectively. When we excluded these studies, the null 
association previously seen remained. In WAZ studies the study of Sur et al. (d, e, f, g, h, I, j, k, 
l) (2003) were considered as outliers for the same reasons. When we excluded these studies, we 
observed an attenuation of the positive effect of Zn supplementation on WAZ (β = 0.03; CI 95% 
0 to 0.07). The study of Osendrap et al. (b) (2002) was considered as an outlier in the analysis of 
Length. When we excluded this study, the null association previously seen persisted and also the 
heterogeneity (I²= 47%; p= 0.03). 
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Discussion 
Our results indicate that Zn supplementation increases some growth parameters in infants. Zn 
intake had a positive and statistically effect on WAZ (β = 0.06; 95%CI 0.02 to 0.10) and WLZ (β 
= 0.05; 95%CI 0.01 to 0.08). We only found significant heterogeneity while analysing length (I² 
= 45 %, p = 0.03). After stratifying by several factors, heterogeneity disappeared.  
To our knowledge, this meta-analysis is the only in providing an estimate of the dose-response 
relationship of Zn intake and growth parameters in infants aged 1–12 months. An infant with a 
Zn intake of 10 mg/day has a WAZ and WLZ that is 4 % higher than an infant who has a Zn 
intake of 5 mg/day. However, interpretation of these results should be carefully considered for a 
number of reasons. It is a well acknowledged that when many statistical comparisons are carried 
out, one or more might reach significance due to chance alone (Bland & Altman 1995). Although 
meta-analysis are increasingly used to consolidate results from multiple studies of the same topic 
and to develop evidence-based policies for clinical practice and public health programmes, the 
reliability of reached conclusions depends on the methodological quality of the original studies, 
the appropriateness of the study inclusion criteria, the thoroughness of the review and the 
synthesis of information (Brown et al. 2002). It is unlikely that confounding factors might have 
affected our results since all the studies included in our meta-analyses are RCTs. However, if 
some baseline differences were observed because any failure in the randomize process, several 
authors performed an adjustment of initial differences (Arsenault et al. 2008 and Rivera et al. 
1998). Other authors assumed no initial differences. The only exception was Bates et al (1993) 
that did not mention anything regarding this matter.   
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A limitation of this study was the small amount of studies that were eligible for inclusion in this 
meta-analysis. Although nineteen RCTs of the effect of Zn supplementation on infant’s growth 
were included, for the association between Zn intake and head circumference the meta-analysis 
only included 4 studies which led to a reduction of the statistical power to detect significant 
differences.  
Age of the study populations considered in this meta-analysis was another important point. We 
believe that there was no reason to exclude any study that did not adhere exclusively to the group 
of 0 to 12 months of age. For this reasons, we took into account all the studies which included 
this age group in the study, even if they were not analysed according to their age group (Bates et 
al. 1993; Gardner et al. 2005; Hamadani et al. 2001; Meeks Gardner et al. 1998; Müller et al. 
2003; Ninh et al. 1996; Walravens et al. 1989) and assumed the consequences of this possible 
bias. 
The small magnitude of effect that we observed might be due to some effect modifiers that 
should be considered whenever the effect of Zn deficiency on growth is being evaluated. Those 
include factors in close relation to infancy such as prematurity, low birth-weight (LBW), 
breastfeeding, protein energy malnutrition, infectious morbidity, poverty, and social deprivation, 
the pre-existing Zn status of the study subjects; and others directly related to Zn such as content 
and bioavailability of Zn in local diets. Moreover, methodological aspects of these studies, such 
as variations in the dose, chemical form, method of administration of Zn and duration of 
supplementation, may have influenced our results (Brown et al. 2002). Some of these aspects 
were analysed in the sub-groups analyses of the meta-analysis. Duration of the intervention in 
some studies was other possible explication to the small magnitude of the effect founded. Time 
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of the intervention appears to be too short to obtain a positive impact on growth (Heinig et al. 
2006; Lind et al. 2004; Meeks Gardner et al. 1998; Sur et al. 2003). However, this becomes more 
relevant when studies are conducted in LBW infants because the low weight together with the 
immaturity associated with premature infants requires adjustment of gestational age with 
chronological age for proper assessment of catch-up growth (Rugolo 2005). This is the case of 
the Meeks Gardner and Sur’s studies (Meeks Gardner 1998; Sur et al. 2003) which were 
conducted in infants with a poor nutritional status. Nonetheless, on healthy infants Lind et al. 
(2004) reported improvements in growth in a 3 month period. Opposite results were obtained by 
Bates et al. and Heinig et al. (1993; 2006) which failed to observe a positive effect in longer 
periods of time. Also Rivera et al. and Umeta et al. (1998; 2000) found that MUAC did not 
change due to the extension of the supplementation period which was apparently too short to find 
any measurable effect. Thus, clinical trials are required to analyze the long-term effects on 
growth of Zn supplementation before reaching significant conclusions. 
Other consideration to take into account is that the data from our meta-analysis was obtained 
generally from countries in a developing stage and included data from LBW and malnourished 
infants which might have resulted in the poor effect we found. Several studies have been carried 
out worldwide and many of these showed a positive effect of Zn supplementation on growth 
among groups of children who were nutritionally disadvantaged in some way, including stunted 
children (Walravens et al. 1989; Wasantwisut et al. 2006), and in particular among malnourished 
children (Arsenault et al. 2008; Ninh et al. 1996; Rivera et al. 1998). On the other hand, there 
was no growth response to supplementation in healthy Gambian nor healthy USA infants (Bates 
et al. 1993; Heinig et al. 2006). A meta-analysis of 25 studies (Brown et al. 1998) of Zn 
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supplements on growth of children in developing countries found smaller but significant effects 
on growth (an effect size of +0.22 for height and +0.26 for weight increments). However, an 
updated version of that meta-analysis (Brown et al. 2002) based on 33 RCT, showed a highly 
significant aggregate effect size of 0.350 (95% CI: 0.189, 0.511) for height, 0.309 (95% CI: 
0.178, 0.439) for weight, and ≈0 for WLZ increments. Thus Zn supplementation on child growth 
has been studied extensively in developing countries, but relatively little information is available 
from industrialized ones (Brown et al. 2002). Therefore, it is unclear whether children in 
industrialized countries would benefit from increased Zn intakes. 
 
In conclusion, our meta-analyses provided us an estimate of the dose-response relation between 
Zn intake and some growth’s parameters (WAZ and WLZ) in infant population. These data can 
be used as complementary evidence for underpinning Zn reference values, although restrictions 
on extrapolation of our results to other populations should be acknowledged mainly to developed 
populations.  
For the others growth’s parameters included in the meta-analyses, no effect was found. Further 
standardized research is urgently needed to reach evidence-based conclusions to clarify the role 
of Zn supplementation upon infant growth mainly in Western populations. 
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Figure 1: Flow diagram for the systematic review. 
Titles and abstracts identified from electronic search and screened 
Master Library of Zinc: n= 5500  
 
Excluded after first screening:                                        
Exclusion / inclusion criteria apply and duplicates removed    
 n = 3339 
Exclusion adults and elderly, children, adolescents, 
pregnant and lactating women     
n = 1817 
Full copies of publications on articles in INFANTS 
population, retrieved and assessed for eligibility                                       
n = 344  
Application inclusion / exclusion form                     
excluded                                                                                 
n = 318 
26 RCTs Papers included for Intake – Status – Health final 
library for meta-analysis and data extraction 
INTAKE – HEALTH relationships 
 
GROWTH: 
19 RCTs (38estimations) included: 
 11 Length  
 11 Weight 
 10 Weight for age z-score (WAZ) 
  9 Length for age z-score (LAZ)  
  8 Weight for length z score (WLZ) 
  4 Head circumference 
  7 Mid upper arm circumference (MUAC) 
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Study or Subgroup
Bates, 1993
Berger, 2006
Dijkhuizen, 2001
Fisher Walker, 2009
Gardner, 2005
Heinig, 2006a
Heinig, 2006b
Ninh, 1996
Osendrap, 2002a
Osendrap, 2002b
Osendrap, 2002c
Rivera, 1998
Walravens, 1989a
Walravens, 1989b
Wasantwisut, 2006
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 21.05, df = 14 (P = 0.10); I² = 33%
Test for overall effect: Z = 0.96 (P = 0.34)
BETA
-0.0180475
0.00734628
0.01466152
-0.0096562
0.00137506
0.00337825
-0.0017323
0.02160029
0.01269063
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-0.0053317
0.00850396
0.03174719
0.03205935
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SE
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0.01320046
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0.0206321
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Weight
10.7%
16.7%
9.5%
6.0%
9.2%
4.4%
4.4%
9.2%
3.3%
0.4%
2.9%
6.7%
1.1%
1.1%
14.3%
100.0%
IV, Random, 95% CI
-0.02 [-0.03, -0.00]
0.01 [-0.00, 0.02]
0.01 [-0.00, 0.03]
-0.01 [-0.04, 0.02]
0.00 [-0.02, 0.02]
0.00 [-0.03, 0.03]
-0.00 [-0.03, 0.03]
0.02 [0.00, 0.04]
0.01 [-0.02, 0.05]
0.12 [0.01, 0.23]
-0.01 [-0.05, 0.04]
0.01 [-0.02, 0.03]
0.03 [-0.04, 0.10]
0.03 [-0.04, 0.10]
-0.01 [-0.02, 0.01]
0.00 [-0.00, 0.01]
BETA BETA
IV, Random, 95% CI
-0.05 -0.025 0 0.025 0.05
 
Figure 2: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (Weight) in infants. 
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Study or Subgroup
Bates, 1993
Berger, 2006
Dijkhuizen, 2001
Fisher Walker, 2009
Gardner, 2005
Heinig, 2006a
Heinig, 2006b
Ninh, 1996
Osendrap, 2002a
Osendrap, 2002b
Osendrap, 2002c
Rivera, 1998
Walravens, 1989a
Walravens, 1989b
Wasantwisut, 2006
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 25.30, df = 14 (P = 0.03); I² = 45%
Test for overall effect: Z = 0.68 (P = 0.50)
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-0.00911733
0.00127531
0.00323455
-0.00132211
-0.00189339
0.00273816
0.00094092
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0.0309756
0.02833152
0.0204524
0.00689355
0.03164554
0.00684012
-0.00263837
SE
0.00350464
0.00163496
0.00284444
0.00395489
0.00510542
0.00523651
0.00493665
0.00536704
0.01361784
0.03556728
0.01450255
0.00475003
0.0218218
0.02387138
0.00183544
Weight
10.1%
16.6%
12.2%
8.9%
6.5%
6.3%
6.8%
6.1%
1.3%
0.2%
1.1%
7.1%
0.5%
0.4%
15.9%
100.0%
IV, Random, 95% CI
-0.01 [-0.02, -0.00]
0.00 [-0.00, 0.00]
0.00 [-0.00, 0.01]
-0.00 [-0.01, 0.01]
-0.00 [-0.01, 0.01]
0.00 [-0.01, 0.01]
0.00 [-0.01, 0.01]
0.01 [-0.00, 0.02]
0.03 [0.00, 0.06]
0.03 [-0.04, 0.10]
0.02 [-0.01, 0.05]
0.01 [-0.00, 0.02]
0.03 [-0.01, 0.07]
0.01 [-0.04, 0.05]
-0.00 [-0.01, 0.00]
0.00 [-0.00, 0.00]
BETA BETA
IV, Random, 95% CI
-0.05 -0.025 0 0.025 0.05
 
 
Figure 3: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (Length) in infants. 
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Study or Subgroup
Heinig, 2006
Meeks Gardner, 1998
Osendrap, 2002
Rivera, 1998
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.53, df = 3 (P = 0.68); I² = 0%
Test for overall effect: Z = 0.19 (P = 0.85)
BETA
0.00126049
0.00590717
-0.0016081
0.0028015
SE
0.00391991
0.00760938
0.00255384
0.00411737
Weight
22.1%
5.9%
52.0%
20.0%
100.0%
IV, Random, 95% CI
0.00 [-0.01, 0.01]
0.01 [-0.01, 0.02]
-0.00 [-0.01, 0.00]
0.00 [-0.01, 0.01]
0.00 [-0.00, 0.00]
BETA BETA
IV, Random, 95% CI
-0.05 -0.025 0 0.025 0.05
 
Figure 4: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (Head Circumference) in infants. 
 
 
 
Study or Subgroup
Arsenault, 2008 a
Arsenault, 2008 b
Bates, 1993
Heinig, 2006
Muller, 2003
Osendrap, 2002
Rivera, 1998
Umeta, 2000 a
Umeta, 2000 b
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 6.91, df = 8 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.98 (P = 0.33)
BETA
-0.0065066
0.00743958
-0.0277362
0.0239698
0.0110113
-0.0049165
0.00328778
0.01146116
0.01285006
SE
0.01271913
0.01260497
0.04472781
0.01905093
0.00982811
0.00534505
0.00761011
0.00859427
0.01165681
Weight
6.2%
6.3%
0.5%
2.8%
10.4%
35.3%
17.4%
13.6%
7.4%
100.0%
IV, Random, 95% CI
-0.01 [-0.03, 0.02]
0.01 [-0.02, 0.03]
-0.03 [-0.12, 0.06]
0.02 [-0.01, 0.06]
0.01 [-0.01, 0.03]
-0.00 [-0.02, 0.01]
0.00 [-0.01, 0.02]
0.01 [-0.01, 0.03]
0.01 [-0.01, 0.04]
0.00 [-0.00, 0.01]
BETA BETA
IV, Random, 95% CI
-0.05 -0.025 0 0.025 0.05
 
Figure 5: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (MUAC: Mid upper arm circumference) in infants. 
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Study or Subgroup
Berger, 2006
Dijkhuizen, 2001
Gardner, 2005
Hamadani, 2001a
Hamadani, 2001b
Lind, 2004
Ninh, 1996
Olney, 2006
Rivera, 1998
Sur, 2003a
Sur, 2003b
Sur, 2003c
Sur, 2003d
Sur, 2003e
Sur, 2003f
Sur, 2003g
Sur, 2003h
Sur, 2003i
Sur, 2003j
Sur, 2003k
Sur, 2003l
Wasantwisut, 2006
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 31.14, df = 21 (P = 0.07); I² = 33%
Test for overall effect: Z = 2.69 (P = 0.007)
BETA
0.0647417
0.0593347
-0.018498
0
0.0633639
0.1202346
0.1387323
-0.032371
-0.018498
-0.045933
-0.053588
-0.038277
0.1071769
0.1454544
0.0535884
0.0688994
0.1913873
0.1531099
0.1531099
0.2526313
0.5511955
0
SE
0.0377112
0.0692402
0.0494441
0.0829569
0.0810719
0.0532252
0.0441472
0.041484
0.0843635
0.0859668
0.127849
0.1122829
0.1209568
0.1256994
0.1405654
0.1492998
0.1485245
0.1447394
0.1441267
0.1569395
0.1565394
0.0477421
Weight
10.6%
5.7%
8.4%
4.5%
4.6%
7.8%
9.4%
9.9%
4.4%
4.2%
2.2%
2.8%
2.5%
2.3%
1.9%
1.7%
1.7%
1.8%
1.8%
1.6%
1.6%
8.7%
100.0%
IV, Random, 95% CI
0.06 [-0.01, 0.14]
0.06 [-0.08, 0.20]
-0.02 [-0.12, 0.08]
0.00 [-0.16, 0.16]
0.06 [-0.10, 0.22]
0.12 [0.02, 0.22]
0.14 [0.05, 0.23]
-0.03 [-0.11, 0.05]
-0.02 [-0.18, 0.15]
-0.05 [-0.21, 0.12]
-0.05 [-0.30, 0.20]
-0.04 [-0.26, 0.18]
0.11 [-0.13, 0.34]
0.15 [-0.10, 0.39]
0.05 [-0.22, 0.33]
0.07 [-0.22, 0.36]
0.19 [-0.10, 0.48]
0.15 [-0.13, 0.44]
0.15 [-0.13, 0.44]
0.25 [-0.05, 0.56]
0.55 [0.24, 0.86]
0.00 [-0.09, 0.09]
0.06 [0.02, 0.10]
BETA BETA
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
 
Figure 6: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (WAZ: Weight for age Z – score) in infants. 
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Study or Subgroup
Berger, 2006
Dijkhuizen, 2001
Gardner, 2005
Hamadani, 2001a
Hamadani, 2001b
Lind, 2004
Ninh, 1996
Olney, 2006
Rivera, 1998
Wasantwisut, 2006
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 10.27, df = 9 (P = 0.33); I² = 12%
Test for overall effect: Z = 0.45 (P = 0.66)
BETA
0.05549291
0.00539406
-0.0554929
0
0.06336391
0.01849764
0.13410786
-0.0369953
0.02774645
-0.0046244
SE
0.0388374
0.0657008
0.0656958
0.0870719
0.0900799
0.0455414
0.0637569
0.0240375
0.0991123
0.0466862
Weight
15.7%
6.3%
6.3%
3.7%
3.5%
12.1%
6.7%
31.2%
2.9%
11.6%
100.0%
IV, Random, 95% CI
0.06 [-0.02, 0.13]
0.01 [-0.12, 0.13]
-0.06 [-0.18, 0.07]
0.00 [-0.17, 0.17]
0.06 [-0.11, 0.24]
0.02 [-0.07, 0.11]
0.13 [0.01, 0.26]
-0.04 [-0.08, 0.01]
0.03 [-0.17, 0.22]
-0.00 [-0.10, 0.09]
0.01 [-0.03, 0.04]
BETA BETA
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
 
 
Figure 7: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (LAZ: Length for age Z- score) in infants.  
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Study or Subgroup
Berger, 2006
Dijkhuizen, 2001
Gardner, 2005
Hamadani, 2001a
Hamadani, 2001b
Lind, 2004
Ninh, 1996
Rivera, 1998
Wasantwisut, 2006
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 9.09, df = 8 (P = 0.33); I² = 12%
Test for overall effect: Z = 2.70 (P = 0.007)
BETA
0.0647417
0.0431525
0.0924882
0
0.0633639
0.1433567
0.0416197
-0.087864
0
SE
0.0327174
0.0637599
0.045111
0.0790938
0.0638779
0.0568378
0.0503126
0.0764765
0.0398559
Weight
23.2%
7.5%
13.8%
5.0%
7.5%
9.2%
11.5%
5.3%
17.0%
100.0%
IV, Random, 95% CI
0.06 [0.00, 0.13]
0.04 [-0.08, 0.17]
0.09 [0.00, 0.18]
0.00 [-0.16, 0.16]
0.06 [-0.06, 0.19]
0.14 [0.03, 0.25]
0.04 [-0.06, 0.14]
-0.09 [-0.24, 0.06]
0.00 [-0.08, 0.08]
0.05 [0.01, 0.08]
BETA BETA
IV, Random, 95% CI
-0.2 -0.1 0 0.1 0.2
 
 
Figure 8: Forest plot of randomized controlled trials evaluating the effect of zinc intake on 
Growth (WLZ: Weight for length Z- score) in infants.  
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Figure 9: WAZ (Kg/age z-score) as a function of dietary zinc intake (mg/day), estimated by 
random effects meta-analyses of RCTs of infants. 
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Figure 10: WLZ (Kg/Length z-score) as a function of dietary zinc intake (mg/day), 
estimated by random effects meta-analyses of RCTs of infants. 
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Table 1: Search strategy: MEDLINE February 2010  
 
(MEDLINE  home page. Available online: http://www.ncbi.nlm.nih.gov/pubmed/) 
No.  Search term 
 
Results 
1 randomized controlled trial.pt. 280,821 
  
2 controlled clinical trial.pt. 79,998  
 
3 randomised.ab. 196,604  
 
4 placebo.ab. 117,891  
 
5 clinical trials as topic.sh. 146,242  
 
6 randomly.ab. 145,491  
 
7 trial.ab. 203,467  
 
8 randomised.ab. 38,423  
 
9 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 734,511  
 
10 (animals not (human and animals)).sh. 4,482,479  
 
11 9 not 10 642,665  
 
12 (cohort* or ''case control*'' or cross-sectional* or ''cross sectional'' or case-
control* or prospective or ''systematic review*'').mp. 
768,885  
 
 
13 exp meta-analysis/ or expmulticenter study/ or follow-up studies/ or 
prospective studies/ or intervention studies/ or epidemiologic studies/ or case-
control studies/ or exp cohort studies/ or longitudinal studies/ or cross-sectional 
studies/ 
1,013,635 
 
  
 
14 13 or 12 1,203,767  
   
15 14 not 10 1,154,385  
 
16 11 or 15 1,599,094 
  
17 ((zinc or zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or 16,681 
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zinc isotope*) adj3 (intake* or diet* or supplement* or deplet* or status or 
serum or plasma or leukocyte or concentration* or expos* or fortif* or urine or 
hair)).ti,ab. 
 
 
 
18 Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or 
Breast feeding/ or exp infant food/ or bottle feeding/ or infant formula/ 
63,098  
 
 
19 exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet 
supplementation/ or dietary intake/ or exp diet restriction/ or exp mineral 
intake/ or Diet/ or Food, Fortified/ or nutrition assessment/ or Nutritive Value/ 
176,014  
 
 
 
20 (intake* or diet* or supplement* or deplet* or status or serum or plasma or 
leukocyte or concentration* or expos* or fortif* or urine or hair).ti,ab. 
3,166,092  
 
 
21 18 or 19 or 20 3,263,114  
 
22 zinc/ 41,027  
 
23 22 and 21 20,745  
 
24 23 or 17 26,943  
 
25 24 and 16 2410  
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Table 2: Characteristics of the 19 (38 estimations) Growth studies included in the meta-analysis 
 
 
Author Study 
year 
Country Sample Age 
range or 
Mean (SD) 
Number of infants (n) Doses of 
Zn/day 
Time of 
the 
interventio
n 
Outcome 
(measure) 
Nutriti
onal 
situati
on 
Risk 
of 
bias¹ 
    C Zn      
Arsenault 
(a) (b) 
2008 Peru 6 to 8 
months 
44 44 36 
38 
3 mg in a 
liquid 
suppleme
nt 3 mg in 
a fortified 
porridge 
24 w Growth: 
MUAC 
Nutriti
onally 
at risk 
High 
risk 
Bates 1993 Gambia 5.7 to 27 
months 
50 53 20 mg 60 w Growth: 
Weight - 
Length 
MUAC 
Health
y 
High 
risk 
Berger 2006 Vietnam 4 to 7 
months 
195 191 10 mg 24 w Growth: 
Weight - 
Length 
WAZ – 
LAZ - WLZ 
Nutriti
onally 
at risk 
Moder
ate 
risk 
Dijkhuizen 2001 Indonesia Mean 4.2 
months 
90 98 7 mg 24 w Growth: 
Weight- 
Length 
WAZ – 
LAZ – 
WLZ 
Poor 
nutriti
onal 
status 
Moder
ate 
risk 
Fischer 
Walker 
2009 Banglade
sh 
6.3 ± 0.3 
months 
140 141 2,8 mg 24 w Growth: 
Weight - 
Nutriti
onally 
Moder
ate 
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Length at risk risk 
Gardner 2005 Jamaica 9 to 30 
months 
59 55 10 mg 24 w Growth: 
Weight - 
Length 
WAZ – 
LAZ - WLZ 
Poor 
nutriti
onal 
status 
Moder
ate 
risk 
Hamadani 
(a) (b) 
2001 Banglade
sh 
1 to 13 
months 
109 101 103 
97 
5 mg 28 w 52 w Growth: 
WAZ – 
LAZ WLZ 
Poor 
nutriti
onal 
status 
High 
risk 
Heinig (a) 
(b) For 
Head 
Circunf. 
2006 USA 3 to 10 
months 
37 37 37 33 
33 
33 
5 mg 16 w 40 w 
24 w 
Growth: 
Weight - 
Length 
MUAC 
Head 
Circumferen
ce 
Health
y 
Low 
risk 
Lind 2004 Indonesia 6 to 12 
months 
164 163 10 mg 8 w Growth: 
WAZ - 
LAZ-WLZ 
Health
y 
Low 
risk 
Meeks 
Gardner 
1998 Jamaica 6 to 24 
months 
24 31 5 mg 12 w Growth: 
Head 
Circumferen
ce 
Poor 
nutriti
onal 
status 
Moder
ate 
risk 
Muller 2003 Burkina 
Faso 
Zn group: 
18.7 ± 7.0 
moPlacebo 
group: 17.6 
± 6.5 mo 
329 332 1,78 mg 24 w Growth: 
MUAC 
Nutriti
onally 
at risk 
Low 
risk 
Ninh 1996 Vietnam 4 to 36 
months 
73 73 10 mg 20 w Growth: 
Weight - 
Length 
WAZ – 
Poor 
nutriti
onal 
status 
Low 
risk 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 C
en
tra
l L
an
ca
sh
ire
] a
t 0
2:2
8 0
4 M
arc
h 2
01
5 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 40
LAZ - WLZ 
Olney 2006 Zanzibar 5 to 12 
months 
58 44 10 mg 24 w Growth: 
WAZ – 
LAZ 
Poor 
nutriti
onal 
status 
High 
risk 
Osendarp(a
) (b) low 
serum zn  
9.18 
µmol/L(c) 
normal 
serum zn  
9.18 
µmol/L 
2002 Banglade
sh 
3 to 5 weeks 13316115 1382 
1117 
5 mg 20 w Growth: 
Weight - 
Length 
MUAC 
Head 
Circumferen
ce 
Health
y 
Moder
ate 
risk 
Rivera 1998 Guatemal
a 
6 to 9 
months 
44 45 10 mg 28 w Growth: 
Weight - 
Length 
WAZ – 
LAZ - 
WLZ- 
MUAC 
Head 
Circumferen
ce 
Nutriti
onally 
at risk 
High 
risk 
 (a) (b) (c) 
(d) (e)Sur 
(f) (g) (h) 
(i) (j) (k) 
(l) 
2003 India 0 to 12 
months 
50 50 50 50 50 
50 50 50 50 50 
50 50 
50 
50 
50 
50 
50 
50 
50 
50 
50 
3,57 
mg3,57 
mg3,57 
mg3,57 
mg3,57 
mg3,57 
mg3,57 
mg3,57 
mg3,57 
1 w 2 w 3 
w 4 w 5 w 
6 w 7 w 8 
w 9 w 10 
w 11 w 12 
w 
Growth : 
WAZ 
Poor 
nutriti
onal 
status 
Moder
ate 
risk 
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50 
50 
50 
mg3,57 
mg3,57 
mg3,57 
mg 
(a) Umeta 
(b) 
2000 Ethiopia Zinc stunted: 
9.5 ± 2.0 mo 
Placebo 
stunted: 9.7 
± 2.0 mo 
Zinc non 
stunted: 9.3 
± 2.1 mo 
Placebo non 
stunted: 9.2 
± 2.0 mo 
47 45 47 
45 
8,57 mg 24 w Growth: 
MUAC 
Health
y 
(stunte
d – 
non 
stunte
d) 
High 
risk 
Walravens 
Boys Girls 
1989 USA 8 to 27 
months 
13 12 13 
12 
5,7 mg 
5,7 mg 
24 w Growth: 
Weight - 
Length 
Nutriti
onally 
at risk 
Low 
risk 
Wasantwis
ut 
2006 Thailand 4 to 6 
months 
153 151 10 mg 24w Growth: 
Weight - 
Length 
WAZ – 
LAZ - WLZ 
Health
y 
Low 
risk 
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Table 3:  Meta-regression. Multivariate adjusted mean beta for Growth (Length) (95% confidence interval) by 
different characteristics of the studies included in the meta-analysis 
 
 n Mean beta’s Confidence interval 
(95%) 
P ANCOVA* 
Growth: Length     
By time      
4 to 20 weeks 5 0.0113 0.008 to 0.0219  
> 20 weeks 10 -0.0026 -0.0089 to 0.0037  
    0.008 
By Dose     
1 to 4 mg 1 -0.0058 -0.0245 to 0.0130  
4,1 to 8 mg 8 0.0162 0.0078 to  0.0245  
8,1 to 12 mg  5 0.0057 -0.0016 to  0.0130  
> 12 mg 1 0.0014 -0.0200 to 0.0229  
    0.023 
By Nutritional situation     
Healthy 7 0.0010 -0.0066 to 0.0086  
Nutritionally at risk 5 0.0128 0.0025 to 0.0230  
Poor nutritional situation 3 -0.0006 -0.0122 to 0.0110  
    0.083 
By Risk of Bias     
Low 6 0.0016 -0.0084 to 0.0116  
Moderate 7 0.0074 -0.0013 to 0.0161  
High 2 0.0042 -0.0105 to 0.0189  
    0.409 
* Adjusted for the rest of variables in the table
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Table 4: Pooled beta (95% confidence intervals) for Growth according to the intervention group.  
              Subgroup analyses. 
 
 Pooled estimates (β) Chi²  (d.f., P)  I² * 
Growth: Length    
All Studies (n=15 )   0.001 (-0.002 to 0.004) 25.30 (14,  0.03) 45% 
By time    
4 to 20 weeks (n=5) 0.01 (0 to 0.02) 4.93 (4, 0.29) 19% 
>  20 weeks -0.001 (-0.003 to 0.002) 15.18 (9, 0.09) 41% 
By dose    
     1 to 4 mg (n=1) 0 (-0.01 to 0.01)   
     4,1 to 8 mg (n=8) 0.003 (0 to 0.01) 7.81 (7,  0.35) 10% 
     8,1 to 12 mg (n=5) 0 (-0.002 to 0.004) 6.85 (4,  0.14) 42% 
     >  12 mg (n=1) 0.01 (-0.02 to 0)   
 
*I² Index measures the extent of the heterogeneity 
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Table 5: Pooled beta (95% confidence intervals) for Growth according to the intervention group. 
               Sensitivity Analyses 
 
 Pooled estimates (β) Chi² (dif, P) I² 
Growth: Weight    
All studies (n=15) 0.004 (-0.004 to 0.01)   21.05 (14,   0.10) 33% 
All Studies excluding 
(n=3) 
 0 (-0.005 to 0.01) 15.53 (11,   0.16)                              29% 
Osendrap et al. 2002  b 0.12 (0.01 to 0.23)   
Walravens et al. 1989  a 0.03 (-0.04 to 0.10)   
Walravens et al. 1989  b 0.03 (-0.04 to 0.10)   
    
Growth: MUAC    
All studies (n=9) 0.003 (-0.003 to 0.01) 6.91 (8,   0.55) 0% 
All Studies excluding 
(n=1) 
0 (-0.003 to 0.01) 6.43 (7,   0.49) 0% 
Bates et al.1993 -0.03 (-0.12 to 0.06)   
    
Growth: WAZ    
All studies (n=22) 0.06 (0.02 to 0.10) 31.14 (21,   0.07) 33% 
All Studies excluding 
(n=9) 
0.03 (0 to 0.07) 15.67 (12,   0.21) 23% 
Sur et al. 2003  d 0.11 (-0.13 to 0.34)   
Sur et al. 2003  e 0.15 (-0.10 to 0.39)   
Sur et al. 2003  f 0.05 (-0.22 to 0.33)   
Sur et al. 2003  g 0.07 (-0.22 to 0.36)   
Sur et al. 2003  h 0.19 (-0.10 to 0.48)   
Sur et al. 2003  i 0.15 (-0.13 to 0.44)   
Sur et al. 2003  j 0.15 (-0.13 to 0.44)   
Sur et al. 2003  k 0.25 (-0.05 to 0.56)   
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Sur et al. 2003  l 0.55 (0.24 to 0.86)   
    
Growth: Length     
All studies (n=15) 0.001 (-0.002 to 0.004) 25.30 (14,   0.03) 45% 
All Studies excluding 
(n=1) 
0 (-0.002 to 0.004) 24.67 (13,   0.03) 47% 
Osendrap et al. 2002  b 0.03 (-0.04 to 0.10)   
 
I² Index measures the extent of the heterogeneity 
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